27 Recruiting Studies at University Of California Davis Comprehensive Cancer Center
Active clinical trials at this research center, sourced directly from the NIH registry.
📍 Sacramento, California
All research centersRecruiting Studies at University Of California Davis Comprehensive Cancer Center
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
Ovarian Epithelial Carcinoma
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
Recurrent B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Metastatic Prostate Carcinoma
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
Advanced Bile Duct Carcinoma
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
View Study & Checklist ➔ 🔵 Active, Not Recruiting Early Phase1 💊 Investigational Drug / Biologic
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
Breast Carcinoma
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
Metastatic Malignant Solid Neoplasm
View Study & Checklist ➔ 🟡 Not Yet Recruiting Phase1 💊 Investigational Drug / Biologic
Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma
Recurrent Multiple Myeloma
View Study & Checklist ➔ 🟡 Not Yet Recruiting Phase1 💊 Investigational Drug / Biologic
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
Metastatic Lung Non-Small Cell Carcinoma
View Study & Checklist ➔ 🟡 Not Yet Recruiting Phase2 💊 Investigational Drug / Biologic
ctDNA-Informed Management of Early-Stage Rectal Cancer
Rectal Adenocarcinoma
View Study & Checklist ➔ 🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
Multiple Myeloma
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
Locally Recurrent Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
Recurrent Follicular Lymphoma
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
Glioblastoma
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Locally Advanced Lung Non-Small Cell Carcinoma
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
Acute Myeloid Leukemia
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Recurrent Non-Muscle Invasive Bladder Carcinoma
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
Advanced Prostate Adenocarcinoma
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Breast Cancer
View Study & Checklist ➔ 🟢 Recruiting Observational / Diagnostic 🩺 Clinical Procedure Protocol
Focal Ablation With Focal Cryotherapy or HIFU for the Treatment of Men With Localized Prostate Cancer
Localized Prostate Carcinoma
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
Recurrent Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
Double-Expressor Lymphoma
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔